I just rewatched the webinar and there were definitely some valuable insights shared. One particularly notable case involved a 60-year-old woman who had undergone 4-5 lines of therapy before receiving Azer-cel, which resulted in a complete response. One of the therapies that failed was Yescarta, a treatment that generated $380millionUSD in Q1 of 2024 alone (1.5bn in 2023). This highlights the remarkable impact Azer-cel can have, even in cases where other significant therapies have not succeeded.
https://www.gilead.com/news-and-press/press-room/press-releases/2024/4/gilead-sciences-announces-first-quarter-2024-financial-results#:~:text=Yescarta®%20(axicabtagene%20ciloleucel)%20sales,”)%20outside%20the%20United%20States.
Media Thread, page-15373
-
- There are more pages in this discussion • 744 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $349.6M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.8¢ | 4.6¢ | $235.5K | 5.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 1742151 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 1452213 | 19 |
View Market Depth
| Last trade - 12.03pm 11/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |